Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. - Wikidata - awgldk - TriplyDB

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

http://www.wikidata.org/entity/Q27851681

about

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Molecular testing in lung cancer in the era of precision medicine Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors CIViC database The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.Current concepts on the molecular pathology of non-small cell lung carcinoma.Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement.Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies Synthesis of a [(18)F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1.Treating ALK-positive lung cancer--early successes and future challenges.Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.Mechanisms of acquired resistance to targeted cancer therapies.ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.Reading between the lines; understanding drug response in the post genomic era.A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.ALK alterations and inhibition in lung cancer.Alectinib for ALK-positive non-small-cell lung cancer.Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.

P2860

785261424cdb551ffe5699b517d0a95a4c08e1d1

P248

Q24310296-2F836F74-BA2F-4557-93A7-0B5CB130D920 Q26795555-E85E1236-6F4A-4F47-826F-F0DFB6D0EDA3 Q26824599-E983B1AB-0ACC-41EB-B282-C4CDABF8E5F9 Q27002155-170EEB15-0BE6-4F62-AD57-98450620E03F Q27310990-F3AA0DD5-DB0A-421E-B695-B83B6E4A03C2 Q27612411-BADF47D4-368C-48FD-BC60-CED983666D36 Q27682565-1A8BC5F5-BAFF-457D-9411-8DB0E173E24B Q27851702-409E8149-9C4C-4161-8EA4-C0FD08E81A6B Q27853072-9D7D5866-727F-4FD2-9CB5-960607DC523A Q28533401-260A5A51-217E-40A2-A5A5-389CDD3CEA84 Q33860904-425B2CC0-A7E5-406A-92A9-3AB4C52FEC96 Q33938441-5A32D250-379F-4CB0-9052-A945693A25FF Q34310062-008638D3-A4C9-431A-8B50-8ED50E619C9A Q34518436-E22A9F98-0D60-4CF1-AEC1-DEC2533BFE42 Q35461464-4062775D-C009-4189-82EA-2ABABBFAB80C Q36114660-C2DF19EC-3C8B-4472-B6DE-44CD30F5A114 Q36121158-140478E7-675E-4C7E-9A66-A76FD64E15BE Q36276264-3F95B964-DECE-471A-8DEC-D23E9821503A Q36405628-9C1BE262-CE2C-477B-98B4-A1AD497AD425 Q36709301-E78C7A30-FDB4-4D65-BA8F-AD3144775CA0 Q36850900-44EEF52E-4740-43CF-BE2B-2AF82B350B05 Q36890803-CB4B1975-9367-475A-9A60-FEF13F4FB648 Q37051546-E8B3AF20-886A-4A84-84B8-4F382190AE73 Q37249366-876358B2-F2BA-43B4-9BF6-E0E89C675682 Q37353087-AC1562E8-3BBB-4253-8941-1E5727375CE1 Q37630493-7694A62D-B4E5-413B-BEC9-AF800307BF99 Q37688093-3A7E0C2A-5015-492A-B384-78AAE56375AC Q37999657-160C4561-3615-4FA7-8255-35AF4C1A06DE Q38002887-9DD0217C-BB7E-4D8B-8DA8-59E85CC90A24 Q38034816-BB782158-DF17-4053-AF2E-2DC83B7C01C5 Q38074590-06FBCCAB-6337-433B-B01A-4C84DF514E24 Q38194999-3CFF7707-C0D3-41BC-AE5D-B93AEF12F97E Q38222600-AF44C156-F737-4FC1-BCF8-CD6C5CFC13BE Q38237654-1031B752-B159-4EDE-ACB3-329B2BDDB1E5 Q38261107-F168EAF2-B124-4A3D-B142-B3A379DC8D8C Q38820412-548F6031-9CCE-4267-8409-22C8699CB547 Q38846027-2882BED6-8893-474D-A324-4A3F444848DB Q38870250-73FEA33C-3456-4115-AB3A-491ECFB3B041 Q38902511-0B880B50-B706-421E-9C7B-2C76D40D96E9 Q39032553-57658FEE-C4CB-4E3A-8C16-5CE215A85E1B

P2860

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

http://www.wikidata.org/entity/Q27851681

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@ast

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@en

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@nl

type

label

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@ast

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@en

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@nl

altLabel

Crizotinib-Resistant Mutants o ...... Accelerated Mutagenesis Screen

@en

prefLabel

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@ast

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@en

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@nl

P1433

Q27851681-09CDDB4A-F5E4-4A44-B813-F362E9F7D780

P1476

Q27851681-3B36D766-FF17-4601-B194-52432D2DB36D

P2093

Q27851681-05A1DD36-D957-437F-BEA5-2A8C858B8099

Q27851681-17C9BD76-BEE1-4267-A838-02BE3828E2F5

Q27851681-377E0195-1FAC-452F-8027-35FFD516FD47

Q27851681-3C7D0A0C-EC91-4C22-BEEB-852A55C8ED64

Q27851681-4B97C019-36A6-4176-BC7E-247284BAC03A

Q27851681-504E6394-769B-4B3D-90EB-12360B7E32A8

Q27851681-597ECF89-48BB-4C79-8032-38753F904D53

Q27851681-70F4FB9C-D6A4-4447-A8A7-23444B44D975

Q27851681-735A8BBC-83A6-4CA1-9994-C644FA45BAB5

Q27851681-87033CB8-EBB5-42E4-ADD7-AF498AD731B0

P2860

Q27851681-000E134D-EFB4-4D75-A0EE-E7B8685C2E93

Q27851681-16799D4F-067F-4D13-A67B-5C0BDBD23275

Q27851681-242EA5FC-E803-4C4D-84A6-97BECA27A3CA

Q27851681-2D0C9430-DDC8-41DF-8AB8-AE8571E9CE02

Q27851681-3EC604E8-E457-4EA4-BC64-CBE87C3F5471

Q27851681-3FB5D88D-2187-4804-8B88-34CE9D292E30

Q27851681-49ECFD75-13E4-4116-AF9C-992638C90FB2

Q27851681-69D2A611-DA59-4202-888E-5C2ABA220540

Q27851681-6C826C05-DF56-4BED-9200-234F6E6D42B5

Q27851681-6E1D461D-AEA8-4907-8F63-C2D9D7FEAACB

P304

Q27851681-E6969D51-5AC0-4DAE-B639-C246A7CDFB86

P31

Q27851681-BEE3DDFA-6393-4DE1-8685-3C62AEF2E14D

P3181

Q27851681-7F26B53E-5915-4A10-A399-A0133481F21F

P356

Q27851681-910BB8D6-F85B-4688-9F6B-3C6B23B79319

P433

Q27851681-12C62FBC-1B01-4DCE-8266-64F0FCE68637

P478

Q27851681-36587B89-E2E9-47A7-B80B-714A9B9C40C5

P577

Q27851681-198781DF-E81E-43F2-BDBF-6B753A50EAB3

P5875

Q27851681-613FC09E-ACBC-4ACF-88EA-FBDD70614413

P698

Q27851681-E43C70AC-60E8-41B2-B0EE-BEF98B6FCDB1

P921

Q27851681-303FD2F2-0C5C-4B0E-AE2E-5B3B01E5F6D8

P932

Q27851681-62979A19-F48B-4EFC-AC72-13ACE43F2E94

P3181

P356

J.1747-0285.2011.01239.X

P1433

Chemical Biology and Drug Design

P1476

Crizotinib-resistant mutants o ...... ccelerated mutagenesis screen.

@en

P2093

David Dalgarno

http://www.w3.org/2001/XMLSchema#string

Frank Wang

http://www.w3.org/2001/XMLSchema#string

Jeffrey Keats

http://www.w3.org/2001/XMLSchema#string

Juan J Miret

http://www.w3.org/2001/XMLSchema#string

Lauren Moran

http://www.w3.org/2001/XMLSchema#string

Narayana I Narasimhan

http://www.w3.org/2001/XMLSchema#string

Qurish K Mohemmad

http://www.w3.org/2001/XMLSchema#string

Rana Anjum

http://www.w3.org/2001/XMLSchema#string

Scott D Wardwell

http://www.w3.org/2001/XMLSchema#string

Sen Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

P304

999-1005

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1902986

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1747-0285.2011.01239.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51754366

http://www.w3.org/2001/XMLSchema#string

P698

22034911

http://www.w3.org/2001/XMLSchema#string

P921

P932

3265718

http://www.w3.org/2001/XMLSchema#string